Key Points
- Andrew Callos, EVP of Cytokinetics, sold 1,809 shares on Dec. 29 at an average price of $62.44 for $112,953.96, leaving him with 51,353 shares (a 3.40% reduction); he also sold 1,042 shares on Dec. 8 and a much larger block of 52,486 shares on Dec. 5 at about $65.95 each.
- Cytokinetics (NASDAQ:CYTK) trades around $61.37 with a market cap near $7.5B and a consensus analyst rating of "Moderate Buy" (consensus price target $83.61); the company reported Q EPS of -$1.54 (slightly beating estimates) but revenue of $1.94M, below expectations.
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 1,809 shares of the business's stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $62.44, for a total transaction of $112,953.96. Following the completion of the transaction, the executive vice president owned 51,353 shares in the company, valued at $3,206,481.32. The trade was a 3.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Andrew Callos also recently made the following trade(s):
- On Monday, December 8th, Andrew Callos sold 1,042 shares of Cytokinetics stock. The stock was sold at an average price of $65.96, for a total transaction of $68,730.32.
- On Friday, December 5th, Andrew Callos sold 52,486 shares of Cytokinetics stock. The shares were sold at an average price of $65.95, for a total transaction of $3,461,451.70.
Cytokinetics Trading Down 0.6%
NASDAQ CYTK opened at $61.37 on Wednesday. The stock has a market cap of $7.50 billion, a P/E ratio of -9.76 and a beta of 0.58. Cytokinetics, Incorporated has a 12 month low of $29.31 and a 12 month high of $70.98. The stock's fifty day moving average price is $63.21 and its 200-day moving average price is $50.13.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.59) by $0.05. The company had revenue of $1.94 million during the quarter, compared to analysts' expectations of $6.05 million. The company's revenue for the quarter was up 318.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.36) EPS. As a group, analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
CYTK has been the subject of several analyst reports. Cantor Fitzgerald restated an "overweight" rating on shares of Cytokinetics in a report on Tuesday, October 21st. HC Wainwright raised their price target on Cytokinetics from $120.00 to $136.00 and gave the company a "buy" rating in a research note on Monday, December 22nd. Stifel Nicolaus raised their price objective on Cytokinetics from $87.00 to $96.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. UBS Group restated a "neutral" rating and issued a $61.00 target price on shares of Cytokinetics in a research note on Monday, December 1st. Finally, Citizens Jmp upped their price objective on shares of Cytokinetics from $78.00 to $88.00 and gave the company a "market outperform" rating in a report on Monday, December 22nd. Fifteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $83.61.
Read Our Latest Research Report on CYTK
Institutional Investors Weigh In On Cytokinetics
A number of institutional investors and hedge funds have recently made changes to their positions in CYTK. HighTower Advisors LLC raised its position in Cytokinetics by 21.8% in the 1st quarter. HighTower Advisors LLC now owns 11,352 shares of the biopharmaceutical company's stock valued at $456,000 after purchasing an additional 2,029 shares in the last quarter. Gabelli Funds LLC lifted its holdings in shares of Cytokinetics by 30.0% in the 1st quarter. Gabelli Funds LLC now owns 6,500 shares of the biopharmaceutical company's stock valued at $261,000 after buying an additional 1,500 shares during the period. Graham Capital Management L.P. acquired a new position in shares of Cytokinetics during the 1st quarter worth $643,000. Vestal Point Capital LP increased its holdings in Cytokinetics by 10.2% in the first quarter. Vestal Point Capital LP now owns 2,590,531 shares of the biopharmaceutical company's stock valued at $104,113,000 after buying an additional 240,531 shares in the last quarter. Finally, Allostery Investments LP grew its holdings in Cytokinetics by 7.7% in the first quarter. Allostery Investments LP now owns 70,000 shares of the biopharmaceutical company's stock valued at $2,813,000 after purchasing an additional 5,000 shares during the last quarter.
Cytokinetics Company Profile
(
Get Free Report)
Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.
The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
